Levodopa/benserazide orally disintegrating tablet
The technology of oral disintegrating tablet and dopasehydrazine is applied in the directions of drug combination, amide active ingredient, nervous system diseases, etc., which can solve the problems of inconvenience, difficulty in taking the whole tablet, inconvenience for patients to use, etc. Cool taste, good taste effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0036] The orally disintegrating tablet of dopaserazide includes the main drug and auxiliary materials, and is characterized in that it is formulated according to the following mass percentages: 30% of the main drug levodopa, 7.5% of the main drug benserazide, and 62.5% of auxiliary materials.
[0037] Levodopa 75g (30.00%)
[0038] Benserazide 18.75g (7.50%)
[0039] Microcrystalline Cellulose 40g (16.00%)
[0040] Mannitol 67g (26.80%)
[0041] Low-substituted hydroxypropyl cellulose 3g (1.20%)
[0042] Lactose 19.25g (7.70%)
[0043] Anhydrous Citric Acid 2g (0.80%)
[0044] Cross-linked polyvinylpyrrolidone 20g (8.00%)
[0045] Cyclamate 1.5g (0.60%)
[0046] Menthol 1.5g (0.60%)
[0047] Micronized silica gel 1g (0.40%)
[0048] Magnesium Stearate 1g (0.40%)
[0049] A total of 1000 tablets were produced
[0050] Among them, lactose and mannitol are fillers, microcrystalline cellulose, cross-linked polyvinylpyrrolidone, and low-substituted hydroxypropyl cellulos...
Embodiment 2
[0058] The orally disintegrating tablet of dopaserazide comprises a main drug and auxiliary materials, and is characterized in that it is prepared according to the following mass percentages: 20% of the main drug levodopa, 5% of the main drug benserazide, and 75% of auxiliary materials.
[0059] Levodopa 50 20.00%
[0060] Benserazide 12.5g (5.00%)
[0061] Microcrystalline Cellulose 90g (36.00%)
[0062] Mannitol 5g (2.00%)
[0063] Low Substituted Hydroxypropyl Cellulose 15g (6.00%)
[0064] Lactose 66g (26.40%)
[0065] Anhydrous citric acid 1g (0.40%)
[0066] Cross-linked polyvinylpyrrolidone 2g (0.80%)
[0067] Cyclamate 1g (0.40%)
[0068] Menthol 1g (0.40%)
[0069] Micronized silica gel 5g (2.00%)
[0070] Magnesium Stearate 1.5g (0.60%)
[0071] A total of 1000 tablets were produced
[0072] The preparation method of the dopaserazide orally disintegrating tablet of the present invention is the same as that in Example 1, and the dopaserazide orally disintegr...
Embodiment 3
[0076] The orally disintegrating tablet of dopaserazide comprises a main drug and auxiliary materials, and is characterized in that it is prepared according to the following mass percentages: 20% of the main drug levodopa, 5% of the main drug benserazide, and 75% of auxiliary materials.
[0077] Levodopa 50g (20.00%)
[0078] Benserazide 12.5g (5.00%)
[0079] Microcrystalline Cellulose 90g (36.00%)
[0080] Mannitol 5g (2.00%)
[0081] Low Substituted Hydroxypropyl Cellulose 15g (6.00%)
[0082] Lactose 66g (26.40%)
[0083] Anhydrous citric acid 1g (0.40%)
[0084] Cross-linked polyvinylpyrrolidone 2g (0.80%)
[0085] Cyclamate 1g (0.40%)
[0086] Menthol 1g (0.40%)
[0087] Micronized silica gel 5g (2.00%)
[0088] Magnesium Stearate 1.5g (0.60%)
[0089] A total of 1000 tablets were produced
[0090] The preparation method of the dopaserazide orally disintegrating tablet of the present invention is the same as that in Example 1, and the dopaserazide orally disint...
PUM
Property | Measurement | Unit |
---|---|---|
hardness | aaaaa | aaaaa |
hardness | aaaaa | aaaaa |
hardness | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com